Fluvastatin (Lescol) treatment of hyperlipidaemia in patients with renal transplants

International Urology and Nephrology

Volumn 29, Issue 1, 1997, Pages 95-106

  Locsey L ^a   Asztalos, L ^a   Kincses, Zs ^a   Balazs G Y ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AZATHIOPRINE; CHOLESTEROL; CREATINE KINASE; CREATININE; CYCLOSPORIN A; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; METHYLPREDNISOLONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION; MALE; MYALGIA; ORAL DRUG ADMINISTRATION;

EID: 0030910564     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02551424     Document Type: Article

References (19)

1. Bortman, G., Sellanes, M., Odell, D. S., Ring, W. S., Olivari, M. T.: Discrepancy between prae and post transplant diagnosis of end-stage dilated cardiomyopathy. Amer. J. Cardiol., 74, 921 (1994).
2. Casteleo, A. M., Grino, J, M., Andres, E., Seros, D., Castineira, M. J., Roca, M., Morero, F., Atalau, J.: HMG-Co-A reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporin A immunosuppression. XIIth Intern. Congr. of Nephrology, Jerusalem, June 13-18, 1993. Abstr. pp. 512.
3. Cosio, F. G., Dillon, J. J., Falkenhain, E., Tesi, J., Henry, M. L., Elkhammas, E. A., Davies, E. A., Bumgardner, G. L., Ferguson, R. M.: Racial differences in renal allograft survival: The role of systemic hypertension. Kidney Int., 47, 1136 (1995).
4. Desylpere, J. P.: The role of HMG-Co-A reductase inhibitors in the treatment of hyperlipidaemia: A review of fluvastatin. Curr. Therap. Res., 56, 112 (1995).
5. Ghods, A. J., Milanian, I., Arghani, H., Ghadiri, G.: The efficacy and safety of fluvastatin in hypercholesterolemia of renal transplant recipients. XXXIInd Eur. Dial. Transpl. Ass. Cong. Athens 1995. June 11-14. Abstr. pp. 303.
6. Goldberg, R. B., Roth, D.: A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Amer. J. Cardiol., 76, Suppl. 107A (1995).
7. Harnett, J. D., Foley, R. N., Kent, G. M., Barre, P. E., Murray, D., Parfrey, P. S.: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int., 47, 884 (1995).
8. Holdaas, H., Hartmann, A., Sentrom, J., Dahl, K. J., Borge, M., Pfister, P.: Fluvastatin safety lowers atherogenic lipids in renal transplant patients receiving cyclosporine. Amer. J. Cardiol., 76, Suppl. 102A (1995).
9. Kasiske, B. L.: Risk factors for cardiovascular disease after renal transplantation. Miner. Electrolyte Metab, 19, 186 (1993).
10. Keane, W. F.: Lipids and the kidney. Kidney Int., 46, 910 (1994).
11. Levy, R. I., Troendle, A. J., Fattu, J. M.: A quarter century of drug treatment of dyslipoproteinemia with a focus on the new HMG-Co-A reductase inhibitor fluvastatin. Circulation, 87, S-III, 45 (1993).
12. Li, P. K. T., Mak, T. W. L., Wang, A. Y., Lee, Y. T., Leung, C. B., Lui, S. F., Lam, C. W. K., Lai, K. N.: The interaction of fluvastatin and cyclosporine A in renal transplant patients with dyslipoproteinaemia. Int. J. Clin. Pharmacol. Ther., 33, 246 (1995).
13. Manske, C. L., Kasiske, B. L.: Lipid abnormalities after renal transplantation. In: Keane, W. F., Stein, J. H. (eds): Contemporary Issues in Nephrology. Vol. 24. Lipids and Renal Disease. Churchill Livingstone, New York 1992, pp. 37-61.
14. Nishizawa, Y., Shoji, T., Nishitani, H., Yarmakawa, M., Konishi, T., Kawasaki, K., Morri, H.: Hypertriglyceridaemia and lowered apolipoprotein CII/CIII ratio in uremia. Effect of fibric acid, clinofibrate. Kidney Int., 44, 1352 (1993).
15. Nilsson, J.: Lipid oxidation, vascular inflammation and coronary atherosclerosis. Transplant. Proc., 25, 2063 (1993).
16. Reade, V., Tailleux, A., Reade, R., Harduin, P., Cachera, C., Tacquet, A., Fruchart, J. C., Fievet, C.: Expression of apolipoprotein B epitopes in low density lipoproteins of hemodialyzed patients. Kidney Int., 44, 1360 (1993).
17. Samuelson, O., Aurell, M., Knight-Gibson, Attman, P. Q.: Apolipoprotein B containing lipoproteins and the progression of renal insufficiency. Nephron, 63, 279 (1993).
18. Traindl, O., Reading, S., Franz, M., Watschinger, B., Klauser, R., Pidlich, H., Widhalm, K., Pohanka, E., Kovarik, J.: Treatment of hyperlipidemic kidney graft recipients with lovastatin: Effect on LDL-cholesterol and lipoprotein(a). Nephron, 62, 394 (1992).
19. Wang, C., Salahuddeen, K., McClain, M., Whitehead, J.: Lipid peroxidation accompanies cyclosporine nephrotoxicity: Effects of vitamin E. Kidney Int., 47, 927 (1995).